Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Sofosbuvir (Sovaldi°). Active against hepatitis C virus, but evaluation is incomplete .

Prescrire international - 1 Jan 2015

Abstract excerpt

About 50% of patients with chronic hepatitis C virus (HCV) genotype 1 infection have a sustained virological response to a 48-week course of the peginterferon alfa + ribavirin combination. Adding a viral protease inhibitor to this combination for 12 to 32 weeks enhances antiviral effects but increases the risk of serious adverse effects. Between 70% and 80% of patients with HCV genotype 2 or 3 infection have a...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antiviral Agents
Share to Enzyme Inhibitors
Share to Evidence-Based Medicine

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Hepacivirus

Share to Hepatitis C, Chronic

Share to Sofosbuvir

Share to Uridine Monophosphate

Share to Viral Nonstructural Proteins

Source

Identifiers

PMID: 25734194

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Sofosbuvir (Sovaldi°). Active against hepatitis C virus, but evaluation is incomplete .PMID 25734194Read ↗

Sofosbuvir (Sovaldi) for the treatment of hepatitis C.Semantic proximity Read ↗

Assessing safety and efficacy of sofosbuvir for the treatment of hepatitis C.Semantic proximity Read ↗

Review article: the efficacy and safety of sofosbuvir, a novel, oral nucleotide NS5B polymerase inhibitor, in the treatment of chronic hepatitis C virus infection.Semantic proximity Read ↗

Sofosbuvir, a nucleotide polymerase inhibitor, for the treatment of chronic hepatitis C virus infectionSemantic proximity Read ↗

Sofosbuvir for previously untreated chronic hepatitis C infection.Semantic proximity Read ↗

Sofosbuvir in the treatment of chronic hepatitis C: new dog, new tricks.Semantic proximity Read ↗

What is the role of sofosbuvir in treating hepatitis C infection?Semantic proximity Read ↗

Nucleotide polymerase inhibitor sofosbuvir plus ribavirin for hepatitis C.Semantic proximity Read ↗

Efficacy and safety of sofosbuvir-containing regimens in chronic hepatitis C patients with genotype 2 and 3: a comprehensive analysis of 18 randomized controlled trials.Semantic proximity Read ↗

Sofosbuvir for the treatment of hepatitis C virus infection.Semantic proximity Read ↗

The evolution of the therapeutic strategy in hepatitis C: features of sofosbuvir and indications.Semantic proximity Read ↗

Simeprevir and sofosbuvir for treatment of hepatitis C infection.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.